[1] |
Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues[J]. Lancet Oncol, 2010, 11(11):1086-1095.
doi: 10.1016/S1470-2045(10)70068-1
pmid: 20932799
|
[2] |
Richardson PG, Mitsiades C, Schlossman R, et al. New drugs for myeloma[J]. Oncologist, 2007, 12(6):664-689.
pmid: 17602058
|
[3] |
中国医师协会血液科医师分会多发性骨髓瘤专业委员会.多发性骨髓瘤周围神经病变诊疗中国专家共识(2015年)[J]. 中华内科杂志, 2015, 54(9):821-824.
|
[4] |
中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2017年修订)[J]. 中华内科杂志, 2017, 56(11):866-870.
|
[5] |
National Cancer Institute.Common Terminology Criteria for Adverse Events(CTCAE) v4.0[EB/OL].[2010-06-14]. https://ctep.cancer.gov/protocolDevelopment/electronic_appplications/ctc.htm
|
[6] |
Weiss L, Silver JW. 轻松学习肌电图:神经传导功能与肌电图检查指南[M]. 元小冬, 译. 北京: 北京大学医学出版社, 2007.
|
[7] |
Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5):277-300.
doi: 10.3322/caac.20073
URL
|
[8] |
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[J]. N Engl J Med, 2005, 352(24):2487-2498.
doi: 10.1056/NEJMoa043445
URL
|
[9] |
Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase Ⅲ HOVON-65/ GMMG-HD4 trial[J]. J Clin Oncol, 2012, 30(24):2946-2955.
doi: 10.1200/JCO.2011.39.6820
pmid: 22802322
|
[10] |
Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma[J]. N Engl J Med, 2016, 375(8):754-766.
doi: 10.1056/NEJMoa1606038
URL
|
[11] |
Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma[J]. Leukemia, 2012, 26(4):595-608.
doi: 10.1038/leu.2011.346
pmid: 22193964
|
[12] |
Rampen AJ, Jongen JL, van Heuvel I, et al. Bortezomib-induced polyneuropathy[J]. Neth J Med, 2013, 71(3):128-133.
pmid: 23712808
|
[13] |
Marmiroli P, Cavaletti G. Drugs for the treatment of peripheral neuropathies[J]. Expert Opin Pharmacother, 2016, 17(3): 381-394.
doi: 10.1517/14656566.2016.1120719
pmid: 26567516
|
[14] |
Duggett NA, Flatters SJL. Characterization of a rat model of bortezomib-induced painful neuropathy[J]. Br J Pharmacol, 2017, 174(24):4812-4825.
doi: 10.1111/bph.14063
URL
|
[15] |
Umapathi T, Chaudhry V. Toxic neuropathy[J]. Curr Opin Neurol, 2005, 18(5):574-580.
doi: 10.1097/01.wco.0000180158.34713.aa
URL
|
[16] |
Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat[J]. Exp Neurol, 2007, 204(1):317-325.
pmid: 17214983
|